Download PDF
Dtsch Med Wochenschr 2012; 137(41): 2117-2122
DOI: 10.1055/s-0032-1305332
Übersicht | Review article
Urologie, Geriatrie
© Georg Thieme Verlag KG Stuttgart · New York

Testosteron im Alter – ein Update

Testosterone in old age – an up-date
A. Hilbert-Walter
1   Klinik für Innere Medizin 2 – Geriatrie des Klinikums Nürnberg, Nürnberg
,
R. Büttner
2   Innere Medizin, Krankenhaus Bogen
,
C. Sieber
1   Klinik für Innere Medizin 2 – Geriatrie des Klinikums Nürnberg, Nürnberg
3   Institut für Biomedizin des Alterns, Friedrich-Alexander-Universität Erlangen-Nürnberg
,
C. Bollheimer
3   Institut für Biomedizin des Alterns, Friedrich-Alexander-Universität Erlangen-Nürnberg
› Author Affiliations
Further Information

Publication History

18 April 2012

17 July 2012

Publication Date:
02 October 2012 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Eine der Menopause vergleichbare Andropause gibt es nicht. Beim Mann kommt es mit zunehmendem Alter allenfalls zu einem graduellen Abfall der Testosteronproduktion. Da nach den Schwellenwerten aktueller Leitlinien ein Androgendefizit bei einem Großteil der über 80-jährigen Männer vorläge, wirft dies insbesondere in der Geriatrie die Frage nach therapeutischen Konsequenzen auf. In zahlreichen Studien korrelierten niedrige Testosteronwerte mit einem erhöhten Mortalitäts- und Morbiditätsrisiko. Ein Kausalitätsgefüge für diese Assoziation konnte bislang jedoch nicht belegt werden, sodass praktisch-klinische Schlussfolgerungen verfrüht sind. Dem im Alter von über 60 Jahren neu festgestellten Adrogendefizit wird bei gleichzeitigem Vorliegen bestimmter Symptome ein Krankheitswert als sogenannter Late-onset-Hypogonadismus (LOH) beigemessen. Die für die Diagnose notwendigen Symptome waren bislang weit gefasst. Auf dem Boden aktuellster Forschungsarbeiten (EMAS-Studie) muss der LOH jedoch eingeschränkt als sexualanamnestisch akzentuiertes Syndrom mit für die Geriatrie nachgeordneter Relevanz gesehen werden. In Assoziationsstudien findet sich ein vager Zusammenhang zwischen Androgendefizit und Gebrechlichkeit (Frailty) bzw. dem assoziierten geriatrischen Syndrom der Sarkopenie, d. h. einer Abnahme von Muskelmasse und Muskelkraft. Therapeutische Ansätze, Sarkopenie durch Testosteronsupplementation zu behandeln, zeigten nur eingeschränkten Erfolg. Mehr noch: Aufgrund des erhöhten Auftretens kardiovaskulärer Ereignisse unter Testosteronsupplementation in der TOM-Studie muss bei der Verordnung von Testosteron aktuell zu besonderer Vorsicht geraten und beim älteren Mann mit kardiovaskulärer Anamnese für ein Moratorium der Testosterongabe plädiert werden.

Abstract

Contrasting the relatively abrupt hormonal changes during female menopause, male reproductive function gradually declines during aging. This leads to the formal diagnosis of androgen deficiency in many apparently healthy 80-year-old men, when conventional thresholds are applied, and consequently to the question of androgen substitution in geriatric medicine. Although many clinical studies have documented a correlation between low plasma testosterone levels and mortality a clear causal relationship – which would imply immanent substitution therapy – has not been demonstrated. With this in mind, the diagnosis of late-onset hypogonadism (LOH) should only be made when testosterone-deficiency related symptoms concur with low testosterone levels. Which exact symptoms justify the diagnosis of LOH, however, is not sharply defined. Using criteria defined in the recent EMAS study, LOH might even be an over-diagnosed entity without huge relevance in geriatrics. Low testosterone levels are associated with frailty, but testosterone supplementation has only shown limited effects on age-related sarcopenia. Moreover: the increased incidence of cardiovascular events in the TOM study should be a caveat and lead to a moratorium for uncritical testosterone supplementation in aging men with cardiovascular diseases.

Schlüsselwörter

Testosteron - Androgendefizit - Late-onset-Hypogonadismus - Gebrechlichkeit - Sarkopenie

Keywords

testosterone - androgen deficiency - late-onset-hypogonadism - frailty - sarcopenia
 

  • Literatur

  • 1 Araujo AB, Dixon JM, Suarez EA et al. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96: 3007-3019
    CrossrefPubMedGoogle Scholar
  • 2 Atkinson RA, Srinivas-Shankar U, Roberts SA et al. Effects of testosterone on skeletal muscle architecture in intermediate-frail and frail elderly men. J Gerontol A Biol Sci Med Sci 2010; 65: 1215-1219
    PubMedGoogle Scholar
  • 3 Basaria S, Coviello AD, Travison TG et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109-122
    CrossrefPubMedGoogle Scholar
  • 4 Bhasin S, Cunningham GR, Hayes FJ et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 2536-2559
    CrossrefPubMedGoogle Scholar
  • 5 Bischoff-Ferrari HA, Orav EJ, Dawson-Hughes B. Additive benefit of higher testosterone levels and vitamin D plus calcium supplementation in regard to fall risk reduction among older men and women. Osteoporos Int 2008; 19: 1307-1314
    CrossrefPubMedGoogle Scholar
  • 6 Brambilla DJ, Matsumoto AM, Araujo AB et al. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab 2009; 94: 907-913
    CrossrefPubMedGoogle Scholar
  • 7 Cattabiani C, Basaria S, Ceda GP et al. Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men. J Endocrinol Invest 2012; 35: 104-120
    PubMedGoogle Scholar
  • 8 Cawthon PM, Ensrud KE, Laughlin GA et al. Sex hormones and frailty in older men: the osteoporotic fractures in men (MrOS) study. J Clin Endocrinol Metab 2009; 94: 3806-3815
    CrossrefPubMedGoogle Scholar
  • 9 Corona G, Monami M, Rastrelli G et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl 2011; 34: 528-540
    CrossrefPubMedGoogle Scholar
  • 10 Corona G, Rastrelli G, Vignozzi L et al. Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab 2011; 25: 337-353
    CrossrefPubMedGoogle Scholar
  • 11 Falahati-Nini A, Riggs BL, Atkinson EJ et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000; 106: 1553-1560
    CrossrefPubMedGoogle Scholar
  • 12 Fernández-Balsells MM, Murad MH, Lane M et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95: 2560-2575
    CrossrefPubMedGoogle Scholar
  • 13 Fink HA, Ewing SK, Ensrud KE et al. Association of Testosterone and Estradiol Deficiency with Osteoporosis and Rapid Bone Loss in Older Men. J Clin Endocrinol Metab 2006; 91: 3908-3915
    CrossrefPubMedGoogle Scholar
  • 14 Fried LP, Tangen CM, Walston J et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56: 146-156
    CrossrefPubMedGoogle Scholar
  • 15 Gray A, Feldman HA, McKinlay JB et al. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991; 73: 1016-1025
    CrossrefPubMedGoogle Scholar
  • 16 Harman SM, Metter EJ, Tobin JD et al. Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724-731
    CrossrefPubMedGoogle Scholar
  • 17 Huhtaniemi I, Forti G. Male late-onset hypogonadism: pathogenesis, diagnosis and treatment. Nat Rev Urol 2011; 8: 335-344
    CrossrefPubMedGoogle Scholar
  • 18 Hyde Z, Flicker L, Almeida OP et al. Low free testosterone predicts frailty in older men: the health in men study. J Clin Endocrinol Metab 2010; 95: 3165-3172
    CrossrefPubMedGoogle Scholar
  • 19 Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005; 26: 833-876
    CrossrefPubMedGoogle Scholar
  • 20 Kenny AM, Kleppinger A, Annis K et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc 2010; 58: 1134-1143
    CrossrefPubMedGoogle Scholar
  • 21 Krasnoff JB, Basaria S, Pencina MJ et al. Free testosterone levels are associated with mobility limitation and physical performance in community-dwelling men: the Framingham Offspring Study. J Clin Endocrinol Metab 2010; 95: 2790-2799
    CrossrefPubMedGoogle Scholar
  • 22 Mellström D, Vandenput L, Mallmin H et al. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res 2008; 23: 1552-1560
    CrossrefPubMedGoogle Scholar
  • 23 Mohr BA, Bhasin S, Kupelian V et al. Testosterone, sex hormone-binding globulin, and frailty in older men. J Am Geriatr Soc 2007; 55: 548-555
    CrossrefPubMedGoogle Scholar
  • 24 Ruige JB, Mahmoud AM, De Bacquer D et al. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart 2011; 97: 870-875
    CrossrefPubMedGoogle Scholar
  • 25 Saad F, Aversa A, Isidori AM et al. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev 2012; 8: 131-143
    CrossrefPubMedGoogle Scholar
  • 26 Sattler F, Bhasin S, He J et al. Testosterone threshold levels and lean tissue mass targets needed to enhance skeletal muscle strength and function: the HORMA trial. J Gerontol A Biol Sci Med Sci 2011; 66: 122-129
    PubMedGoogle Scholar
  • 27 Schatzl G, Madersbacher S, Temml C et al. Serum androgen levels in men: impact of health status and age. Urology 2003; 61: 629-633
    CrossrefPubMedGoogle Scholar
  • 28 Seftel AD, Miner MM, Kloner RA et al. Office evaluation of male sexual dysfunction. Urol Clin North Am 2007; 34: 463-482
    CrossrefPubMedGoogle Scholar
  • 29 Shelton JB, Rajfer J. Androgen deficiency in aging and metabolically challenged men. Urol Clin North Am 2012; 39: 63-75
    CrossrefPubMedGoogle Scholar
  • 30 Shores MM, Matsumoto AM, Sloan KL et al. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006; 166: 1660-1665
    CrossrefPubMedGoogle Scholar
  • 31 Shores MM, Moceri VM, Gruenewald DA et al. Low testosterone is associated with decreased function and increased mortality risk: a preliminary study of men in a geriatric rehabilitation unit. J Am Geriatr Soc 2004; 52: 2077-2081
    CrossrefPubMedGoogle Scholar
  • 32 Srinivas-Shankar U, Roberts SA, Connolly MJ et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010; 95: 639-650
    CrossrefPubMedGoogle Scholar
  • 33 Tivesten A, Vandenput L, Labrie F et al. Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab 2009; 94: 2482-2488
    CrossrefPubMedGoogle Scholar
  • 34 Tracz MJ, Sideras K, Boloña ER et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab 2006; 91: 2011-2016
    CrossrefPubMedGoogle Scholar
  • 35 Travison TG, Basaria S, Storer TW et al. Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci 2011; 66: 1090-1099
    PubMedGoogle Scholar
  • 36 Vermeulen A, Kaufman JM, Giagulli VA. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J Clin Endocrinol Metab 1996; 81: 1821-1826
    CrossrefPubMedGoogle Scholar
  • 37 Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666-3672
    CrossrefPubMedGoogle Scholar
  • 38 Vikan T, Schirmer H, Njølstad I et al. Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromsø Study. Eur J Endocrinol 2009; 161: 435-442
    CrossrefPubMedGoogle Scholar
  • 39 Wang C, Nieschlag E, Swerdloff R et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008; 159: 507-514
    CrossrefPubMedGoogle Scholar
  • 40 Wu FC, Tajar A, Beynon JM et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010; 363: 123-135
    CrossrefPubMedGoogle Scholar
  • 41 Zitzmann M. Die Therapie des Hypogonadismus des Mannes. Internist (Berl.) 2008; 49: 559-569
    CrossrefPubMedGoogle Scholar